AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26172564 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM patients
Number of subjects: 0
Study 23129746 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide (BuCy)
Number of subjects: 126
Study 23129746 — intervention group
Group type: COMPARATOR
Intervention: Busulfan plus fludarabine (BuFlu)
Number of subjects: 126
Study 20831649 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix™ (Glaxo Smithkline Biologicals)
Number of subjects: 160
Study 20831649 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRII® (Merck & Co., Inc.)
Number of subjects: 160
Study 20831649 — intervention group
Group type: COMPARATOR
Intervention: Priorix™ and MMRII®
Number of subjects: 160
Study 19496762 — intervention group
Group type: EXPERIMENTAL
Intervention: +4 degrees C Ringer's solution with a target temperature of 33 degrees C
Number of subjects: 37
Study 19496762 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid therapy
Number of subjects: 37
Study 16943110 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.3 IU/kg)
Number of subjects: 120
Study 16943110 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 15457411 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth stem (Ra 17)
Number of subjects: 237
Study 15457411 — intervention group
Group type: COMPARATOR
Intervention: Rough stem (Ra 170)
Number of subjects: 237
Study 12369275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 390
Study 12369275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 9820990 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 0
Study 9820990 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study 9820990 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-selective protocol (recombinant tissue plasminogen activator in anterior acute myocardial infarction, streptokinase in non-anterior acute myocardial infarction)
Number of subjects: 0
Study 7641666 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental videotape with a culturally relevant context emphasizing personal loss
Number of subjects: 100
Study 7641666 — intervention group
Group type: COMPARATOR
Intervention: Gender-ethnicity-matched control condition (videotape presented by an African American woman)
Number of subjects: 100
Study 7641666 — intervention group
Group type: COMPARATOR
Intervention: Ethnicity-matched information control videotape
Number of subjects: 100
Study 2766658 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Number of subjects: 60
Study 2766658 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60
Study 2766658 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 60
Study 2766658 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 60
Study 16339 — intervention group
Group type: EXPERIMENTAL
Intervention: rimiterol
Number of subjects: 60
Study 16339 — intervention group
Group type: COMPARATOR
Intervention: terbutaline
Number of subjects: 60
Study 31982915 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear Activator (HGA)
Number of subjects: 52
Study 31982915 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-Block (TB)
Number of subjects: 52
Study 31982915 — intervention group
Group type: COMPARATOR
Intervention: Both HGA and TB
Number of subjects: 52
Study 27846092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic‐euglycemic clamp (0.1 U/kg/hr)
Number of subjects: 30
Study 27846092 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 30
Study 25786741 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 250
Study 25786741 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depression
Number of subjects: 250
Study 23295625 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF/SiO2‐based toothpaste (1,100 µg F/g as labeled, 1,129.7 ± 49.4 µg F/g soluble fluoride as analyzed)
Number of subjects: 20
Study 23295625 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2FPO3/CaCO3‐based toothpaste (1,450 µg F/g as labeled, 1,122.4 ± 76.4 µg F/g soluble fluoride as analyzed)
Number of subjects: 20
Study 23295625 — intervention group
Group type: COMPARATOR
Intervention: Purified water (control)
Number of subjects: 20
Study 20702058 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based rehabilitation programme
Number of subjects: 143
Study 20702058 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling programme
Number of subjects: 143
Study 19812173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal food supplementation fortified with multiple micronutrients (FFS)
Number of subjects: 1296
Study 19812173 — intervention group
Group type: COMPARATOR
Intervention: MMN supplementation (control)
Number of subjects: 1296
Study 16900825 — intervention group
Group type: EXPERIMENTAL
Intervention: Noble-metal metal-ceramic crowns
Number of subjects: 95
Study 15020281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone before chemotherapy
Number of subjects: 95
Study 15020281 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 95
Study 11736726 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy (proton pump inhibitor-based)
Number of subjects: 2102
Study 11736726 — intervention group
Group type: EXPERIMENTAL
Intervention: Successfully H. pylori eradicated patients
Number of subjects: 2102
Study 11736726 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessfully H. pylori eradicated patients
Number of subjects: 2102
Study 11736726 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing rates
Number of subjects: 2102
Study 10212830 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol administered to STZ diabetic rats and rhesus monkeys
Number of subjects: 0
Study 10212830 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol administered to humans with impaired glucose tolerance
Number of subjects: 0
Study 10212830 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol administered to women with PCOS
Number of subjects: 0
Study 30151230 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (S)
Number of subjects: 71
Study 30151230 — intervention group
Group type: COMPARATOR
Intervention: Non-soy protein (NS)
Number of subjects: 71
Study 28271532 — intervention group
Group type: EXPERIMENTAL
Intervention: Strip patch test
Number of subjects: 132
Study 28271532 — intervention group
Group type: COMPARATOR
Intervention: Conventional patch test
Number of subjects: 132
Study 28271532 — intervention group
Group type: COMPARATOR
Intervention: Nickel sulfate 5% pet.
Number of subjects: 132
Study 28271532 — intervention group
Group type: COMPARATOR
Intervention: Potassium dichromate 0.5% pet.
Number of subjects: 132
Study 28271532 — intervention group
Group type: COMPARATOR
Intervention: Lanolin alcohol 30% pet.
Number of subjects: 132
Study 25667975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cytology and bi-marker CADM1/MAL-methylation analysis
Number of subjects: 364
Study 25667975 — intervention group
Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 364
Study 22992166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat(®)
Number of subjects: 20
Study 22992166 — intervention group
Group type: COMPARATOR
Intervention: Over-ground gait training (OGT)
Number of subjects: 20
Study 19476623 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cemented hemiarthroplasty
Number of subjects: 200
Study 19476623 — intervention group
Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty
Number of subjects: 200
Study 19476623 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 200
Study 17348460 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) followed by cisplatin (75 mg/m2)
Number of subjects: 120
Study 17348460 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2 i.v.) and cyclophosphamide (700 mg/m2 i.v.)
Number of subjects: 120
Study 15096238 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta9 Tetrahydrocannabinol (THC)
Number of subjects: 34
Study 15096238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 34
Study 15096238 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of THC and CBD
Number of subjects: 34
Study 15096238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11230751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interferon (IFN) and ribavirin for either 24 or 48 weeks
Number of subjects: 124
Study 11230751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interferon (IFN) and ribavirin
Number of subjects: 124
Study 9648961 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. (BD group)
Number of subjects: 32
Study 9648961 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.i.d. (ICS group)
Number of subjects: 32
Study 9648961 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (BD group)
Number of subjects: 32
Study 9648961 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (ICS group)
Number of subjects: 32
Study 9648961 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 32
Study 8076625 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid carbohydrate intake (S)
Number of subjects: 32
Study 8076625 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal energy fluid intake (F)
Number of subjects: 32
Study 8076625 — intervention group
Group type: COMPARATOR
Intervention: Fluid placebo (P)
Number of subjects: 32
Study 2916540 — intervention group
Group type: EXPERIMENTAL
Intervention: Know Your Body program
Number of subjects: 1234
Study 799978 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 25 mg orally twice daily
Number of subjects: 126
Study 799978 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg orally twice daily
Number of subjects: 126
Study 31676109 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 0
Study 31676109 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 0
Study 31676109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31500557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory transcranial direct current stimulation
Number of subjects: 11
Study 31500557 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 27753785 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity meeting recommendations
Number of subjects: 219
Study 27753785 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean daily intensity level of 10-minute activity sessions
Number of subjects: 219
Study 27753785 — intervention group
Group type: EXPERIMENTAL
Intervention: Good cardiorespiratory fitness (highest tertile)
Number of subjects: 219
Study 27753785 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest third for the modified push-up test
Number of subjects: 219
Study 25413377 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid continuous infusion (CI)
Number of subjects: 22
Study 25413377 — intervention group
Group type: COMPARATOR
Intervention: Linezolid intermittent infusion (II)
Number of subjects: 22
Study 24151141 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based psychotherapy for PTSD (8 sessions)
Number of subjects: 92
Study 21688301 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50mg subcutaneously weekly)
Number of subjects: 16
Study 21688301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21688301 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept and Placebo
Number of subjects: 16
Study 21688301 — intervention group
Group type: EXPERIMENTAL
Intervention: IMACS and other outcome measures
Number of subjects: 16
Study 19879233 — intervention group
Group type: COMPARATOR
Intervention: Tat vaccine administered 5 times monthly, subcutaneously in alum or intradermically alone at 7.5 microg, 15 microg or 30 microg
Number of subjects: 0
Study 19879233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat vaccine
Number of subjects: 0
Study 17726413 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 10-15 mcg/kg
Number of subjects: 87
Study 17726413 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine sulfate (IV morphine) 0.1 mg/kg
Number of subjects: 87
Study 17726413 — intervention group
Group type: COMPARATOR
Intervention: Both OTFC and IV morphine
Number of subjects: 87
Study 15478494 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% hydrogen peroxide strips
Number of subjects: 37
Study 15478494 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3% hydrogen peroxide strips
Number of subjects: 37
Study 15478494 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide strips
Number of subjects: 37
Study 11419655 — intervention group
Group type: EXPERIMENTAL
Intervention: KPI‐185
Number of subjects: 0
Study 11419655 — intervention group
Group type: COMPARATOR
Intervention: KPI‐wild type
Number of subjects: 0
Study 11419655 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 0
Study 9577286 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (eutectic mixture of local anaesthetics)
Number of subjects: 19
Study 9577286 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 19
Study 7697403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg per day)
Number of subjects: 0
Study 7697403 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation and fish oil
Number of subjects: 0
Study 7697403 — intervention group
Group type: COMPARATOR
Intervention: Diuretics and dietary salt reduction
Number of subjects: 0
Study 3126349 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min
Number of subjects: 129
Study 3126349 — intervention group
Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 129
Study 3126349 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 129
Study 31805922 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal&Protect® (Group B)
Number of subjects: 60
Study 31805922 — intervention group
Group type: EXPERIMENTAL
Intervention: DentinoCer (Group C)
Number of subjects: 60
Study 31805922 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment (Group A)
Number of subjects: 60
Study 28285395 — intervention group
Group type: EXPERIMENTAL
Intervention: OR-fill
Number of subjects: 59
Study 28285395 — intervention group
Group type: COMPARATOR
Intervention: PACU-fill
Number of subjects: 59
Study 25463415 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided arm
Number of subjects: 151
Study 25463415 — intervention group
Group type: COMPARATOR
Intervention: Standard of care arm
Number of subjects: 151
Study 25463415 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related SAEs
Number of subjects: 151
Study 25463415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing SAEs
Number of subjects: 151
Study 25463415 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the highest risk quartile
Number of subjects: 151
Study 23458225 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 40 mg
Number of subjects: 132
Study 23458225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 7.5 mg
Number of subjects: 132
Study 23458225 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 132
Study 21206244 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia spectrum disorders
Number of subjects: 263
Study 21206244 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 263
Study 21206244 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 263
Study 21206244 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical anhedonia
Number of subjects: 263
Study 21206244 — intervention group
Group type: EXPERIMENTAL
Intervention: Social and physical anhedonia
Number of subjects: 263
Study 19476983 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous interferential (IF) electrostimulation; 18 courses, 20 minutes, 3 times per week, low-frequency current, duration of 250 microseconds, repetition time of 6.6 seconds.
Number of subjects: 30
Study 19476983 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 17904983 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (250 microg intravenously)
Number of subjects: 110
Study 17904983 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (400 microg intravenously)
Number of subjects: 110
Study 17904983 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 110
Study 17904983 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 110
Study 15150840 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of combined AZT/3TC tablets
Number of subjects: 24
Study 15150840 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study 11488797 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 44
Study 11488797 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients undergoing surgery for non-malignant conditions)
Number of subjects: 44
Study 11488797 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative period (3 months following tumour resection)
Number of subjects: 44
Study 9631330 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Axis (SA)
Number of subjects: 9
Study 9631330 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Lite (SL)
Number of subjects: 9
Study 9631330 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex Foot (FF)
Number of subjects: 9
Study 9631330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial amputees (TT) overall
Number of subjects: 9
Study 7998630 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS intervention group
Number of subjects: 197
Study 7998630 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 197
Study 2662700 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionyl GH (somatrem), 2 IU per m2 body surface s.c. daily
Number of subjects: 30
Study 2662700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 30148987 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept (0.5 mg) administered intravitreally once monthly for the first 3 months, then once quarterly until month 12.
Number of subjects: 114
Study 30148987 — intervention group
Group type: COMPARATOR
Intervention: Sham control group received first 3 monthly sham injections followed by 3 monthly injections of conbercept (0.5 mg) until month 12.
Number of subjects: 114
Study 27149055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 120
Study 27149055 — intervention group
Group type: COMPARATOR
Intervention: 400 IU vitamin D3
Number of subjects: 120
Study 25010554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1000 mg daily
Number of subjects: 28
Study 25010554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22170716 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (2 mg/d) for the first 6 months
Number of subjects: 16
Study 22170716 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) for the remaining 18 months
Number of subjects: 16
Study 22170716 — intervention group
Group type: COMPARATOR
Intervention: GH therapy
Number of subjects: 16
Study 20128040 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 28
Study 20128040 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxant medication
Number of subjects: 28
Study 17912222 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 0
Study 17912222 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 0
Study 17912222 — intervention group
Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) with conventional dialysis solutions
Number of subjects: 0
Study 17912222 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin based solution
Number of subjects: 0
Study 16288443 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal blood oxygenation and ozonation (EBOO)
Number of subjects: 28
Study 16288443 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prostacyclin
Number of subjects: 28
Study 16288443 — intervention group
Group type: EXPERIMENTAL
Intervention: EBOO
Number of subjects: 28
Study 16288443 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin
Number of subjects: 28
Study 12163294 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency percussive ventilation (HFPV)
Number of subjects: 35
Study 12163294 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 35
Study 10450629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 8677156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytostatic agents (VCR + Rub, L‐aspa, CY, Ara‐C)
Number of subjects: 21
Study 2337243 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural adrenaline
Number of subjects: 84
Study 2337243 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm injectate
Number of subjects: 84
Study 2337243 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural fentanyl
Number of subjects: 84
Study 2337243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 120341 — intervention group
Group type: EXPERIMENTAL
Intervention: Doleron (dextropropoxyphene, acetylsalicylic acid, phenazone, caffeine and Transergan)
Number of subjects: 112
Study 120341 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra 2167 (dextropropoxyphene and acetylsalicylic acid)
Number of subjects: 112
Study 120341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112